In vitro and in vivo CYP3A64 induction and inhibition studies in rhesus monkeys: A preclinical approach for CYP3A-mediated drug interaction studies

Drug Metabolism and Disposition

Volumn 34, Issue 9, 2006, Pages 1546-1555

  Prueksaritanont, Thomayant ^a   Kuo, Yuhsin ^a   Tang, Cuyue ^a   Li, Chunze ^a   Qiu, Yue ^a   Lu, Bing ^a   Strong Basalyga, Kristie ^a   Richards, Karen ^a   Carr, Brian ^a   Lin, Jiunn H ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 3A; CYTOCHROME P450 3A4; CYTOCHROME P450 3A64; CYTOCHROME P450 INHIBITOR; MESSENGER RNA; MIDAZOLAM; N-[2(-HYDROXY-1-INDANYL-5-[2-(1,1-DIMETHYLETHYLAMINOCARBONYL)-4-[(FURO[2,3-B]PYRIDIN-5-YL)-METHYL]PIPERAZIN-1-YL]-4-HYDROXY-2-PHENYLMETHYLPENTANAMIDE); OXYGENASE; RECOMBINANT CYP3A64; RECOMBINANT PROTEIN; RIFAMPICIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; ENZYME ACTIVITY; GLUCURONIDATION; HUMAN; HUMAN CELL; HYDROXYLATION; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL; LIVER CLEARANCE; LIVER METABOLISM; NONHUMAN; PRIORITY JOURNAL; PROTEIN INDUCTION; RHESUS MONKEY;

ADOLESCENT; ADULT; AGED; ANIMALS; CELLS, CULTURED; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; DRUG EVALUATION, PRECLINICAL; DRUG INTERACTIONS; ENZYME INDUCTION; ENZYME INHIBITORS; ETHERS; FEMALE; HEPATOCYTES; HUMANS; HYDROCARBONS, FLUORINATED; HYDROXYLATION; INFUSIONS, INTRAVENOUS; ISOENZYMES; MACACA MULATTA; MALE; MIDAZOLAM; MIDDLE AGED; MODELS, ANIMAL; RECOMBINANT PROTEINS; RIFAMPIN; RNA, MESSENGER;

MACACA MULATTA;

EID: 33747868126     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.106.009878     Document Type: Article

References (41)

1. Backman JT, Kivistö KT, Olkkola T, and Neuvonen PJ (1998) The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampin. Eur J Clin Pharmacol 54:53-58.
2. Backman JT, Olkkola T, and Neuvonen PJ (1996) Rifampin drastically reduces plasma concentrations and effects of oral midazolam. Clin Pharmacol Ther 59:7-13.
3. Bjornsson TD, Callaghan JT, Einolf HJ, Fisher V, Gan L, Grimm S, Kao J, King SP, Miwa G, Ni L, et al. (2003) The conduct of in vitro and in vivo drug-drug interaction studies: a PhRMA perspective. J Clin Pharmacol 43:443-469.
4. Carr B, Norcross R, Fang Y, Lu P, Rodrigues AD, Shou M, Rushmore T, and Booth-Genthe C (2006) Characterization of the rhesus monkey CYP3A64 enzyme: species comparisons of CYP3A substrate specificity and kinetics using baculovirus-expressed recombinant enzymes. Drug Metab Dispos, in press.
5. Chiba M, Nishimi JA, and Lin JH (1995) Potent and selective inactivation of human liver microsomal cytochrome P-450 isoforms by L-754,394, an investigational human immune deficiency virus protease inhibitor. J Pharmacol Exp Ther 275:1527-1534.
6. Dich J and Grunnet N (1990) Primary cultures of rat hepatocytes, in Methods in Molecular Biology 5 (Pollard JW, ed) pp 161-176, The Humana Press Inc., Clifton, NJ.
7. Dresser GK, Spence JD, and Bailey DG (2000) Pharmacokinetic- pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet 38:41-57.
8. Ernest CS, Hall SD, and Jones DR (2005) Mechanism-based inactivation of CYP3A by HIV protease inhibitors. J Pharmacol Exp Ther 312:583-591.
9. Gibson GG, Plant NJ, Swales KE, Ayrton A, and El-Sankary W (2002) Receptor-dependent transcriptional activation of cytochrome P450 3A genes: induction, mechanisms, species differences and interindividual variations in man. Xenobiotica 32:165-206.
10. 14C-midazolam in humans following oral dosing. Arzneim-Forsch 31:2220-2223.
11. Higashikawa F, Murakami T, Kaneda T, and Takano M (1999) In-vivo and in-vitro metabolic clearance of midazolam, a cytochrome P450 3A substrate, by the liver under normal and increased enzyme activity in rats. J Pharm Pharmacol 514:405-410.
12. Houston JB (1982) Drug metabolite kinetics. Pharmacol Ther 15:521-552.
13. Houston JB and Galetin A (2003) Progress towards prediction of human pharmacokinetic parameters from in vitro technologies. Drug Metab Rev 35:393-415.
14. IgarashiT, Sakuma T, Isogal M, Nagata R, and Kamataki T (1997) Marmoset liver cytochrome P450s: study for expression and molecular cloning of their cDNAs. Arch Biochem Biophys 339:85-91.
15. Ito K, Brown HS, and Houston JB (2004) Database analyses for the prediction of in vivo drug-drug interactions from in vitro data. Br J Clin Pharmacol 57:473-486.
16. Ito K, Ogihara K, Kanamitsu S-I, and Itoh T (2003) Prediction of the in vivo interaction between midazolam and macrolides based on in vitro studies using human liver microsomes. Drug Metab Dispos 31:945-954.
17. Kanazu T, Yamaguchi Y, Okamura N, Baba T, and Koike M (2004) Model for the drug-drug interaction responsible for CYP3A enzyme inhibition. I: evaluation of cynomolgus monkeys as surrogates for humans. Xenobiotica 34:391-402.
18. Kharasch ED, Hoffer C, Whittington D, and Sheffels P (2004) Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone. Clin Pharmacol Ther 76:250-269.
19. Koch I, Weil R, Wolbold R, Brockmöller J, Hustert E, Burk O, Nuessler AC, Neuhaus P, Eichelbaum M, Zanger UM, et al. (2002) Interindividual variability and tissue-specificity in the expression of cytochrome P450 3A mRNA. Drug Metab Dispos 30:1108-1114.
20. LeCluyse EL (2001) Human hepatocyte culture systems for the in vitro evaluation of cytochrome P450 expression and regulation. Eur J Pharm Sci 13:343-368.
21. Lesar TS, Briceland L, and Stein DS (1997) Factors related to errors in medication prescribing. J Am Med Assoc 277:312-317.
22. Li AP, Hartman NR, Lu C, Collins JM, and Strong JM (1999) Effects of cytochrome P450 inducers on 17α-ethinyloestradiol (EE2) conjugation by primary human hepatocytes. Br J Clin Pharmacol 48:733-742.
23. Lin JH, Chiba M, Chen I-W, Vastag KJ, Nishimi JA, Dorsey BD, Michelson SR, and McDaniel SL (1995) Time- and dose-dependent pharmacokinetics of L-754,394, an HIV protease inhibitor, in rats, dogs and monkeys. J Pharmacol Exp Ther 274:264-269.
24. Luo G, Cunningham M, Kim S, Burn T, Lin J, Sinz M, Hamilton G, Rizzo C, Jolley S, Gilbert D, et al. (2002) CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes. Drug Metab Dispos 30:795-804.
25. Mei Q, Tang C, Assang C, Lin Y, Slaughter D, Rodrigues AD, Baillie TA, Rushmore TH, and Shou M (1999) Role of a potent inhibitory monoclonal antibody to cytochrome P-450 3A4 in assessment of human drug metabolism. J Pharmacol Exp Ther 291:749-759.
26. Moldeús P, Hogberg J, and Orrenius S (1978) The isolation and use of liver cells. Methods Enzymol 52:60-71.
27. Niemi M, Backman JT, Fromm MF, Neuvonen PJ, and Kivistö KT (2003) Pharmacokinetic interactions with rifampin: clinical relevance. Clin Pharmacokinet 42:819-850.
28. Prueksaritanont T, Richards KM, Qiu Y, Strong-Basalyga K, Miller A, Li C, Eisenhandler R, and Carlini EJ (2005) Comparative effects of fibrates on drug metabolizing enzymes in human hepatocytes. Pharm Res (NY) 22:71-78.
29. Prueksaritanont T, Zhao J, Ma B, Roadcap B, Tang C, Qiu Y, Liu L, Lin JH, Pearson PG, and Baillie TA (2002) Mechanistic studies on the metabolic interactions between gemfibrozil and statins. J Pharmacol Exp Ther 301:1042-1051.
30. Sanofi-Aventis (2003) Prescribing information on Rafadin (Rifampin), in Physicians' Desk Reference, vol 60, pp 759-762, Medical Economics Co., Montvale, NJ.
31. Sharer JE, Shipley LA, Vandenbranden MR, Binkley SN, and Wrighton SA (1995) Comparisons of phase I and phase II in vitro hepatic enzyme activities of human, dog, rhesus monkey, and cynomolgus monkey. Drug Metab Dispos 23:1231-1241.
32. Soars MG, Petullo DM, Eckstein JA, Kasper SC, and Wrighton SA (2004) An assessment of UDP-glucuronosyltransferase induction using primary human hepatocytes. Drug Metab Dispos 32:140-148.
33. Thummel KE, Shen DD, Podoli TD, Kunze KL, Trager WF, Bacchi CE, Marsh CL, McVicar JP, Barr DM, Perkins JD, et al. (1994) Use of midazolam as a human cytochrome P450 3A probe II. Characterization of inter- and intraindividual hepatic CYP3A variability after liver transplantation. J Pharmacol Exp Ther 271:557-566.
34. Thummel KE and Wilkinson GR (1998) In vitro and in vivo drug interactions involving human CYP3A. Annu Rev Pharmacol Toxicol 38:389-430.
35. Tirona RG, Leake BF, Wolkoff AW, and Kim RB (2003) Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation. J Pharmacol Exp Ther 304:223-228.
36. Tsunoda SM, Velez RL, von Moltke LL, and Greenblatt DJ (1999) Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole. Clin Pharmacol Ther 66:461-471.
37. Tucker GT, Houston JB, and Huang S-M (2001) Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential - towards a consensus. Br J Clin Pharmacol 52:107-117.
38. Weaver RJ (2001) Assessment of drug-drug interactions: concepts and approaches. Xenobiotica 31:499-538.
39. Wen YH, Sahi J, Urda E, Kulkarni S, Rose K, Zheng X, Sinclair JF, Cai H, Storm SC, and Kostrubsky V (2002) Effects of bergamotin on human and monkey drug-metabolizing enzymes in primary cultured hepatocytes. Drug Metab Dipos 30:977-984.
40. Wilkinson GR (1987) Clearance approaches in pharmacology. Pharmacol Rev 39:1-47.
41. Worboys PD and Carlile DJ (2001) Implications and consequences of enzyme induction on preclinical and clinical drug development. Xenobiotica 31:539-556.